Age and cancer type:  Associations with increased odds of receiving a Late Diagnosis in people with advanced cancer.

Author:

Mills Sarah Elizabeth Ellen1,Buchanan Deans2,Donnan Peter T3,Smith Blair H3

Affiliation:

1. University of St Andrews

2. NHS Tayside

3. University of Dundee

Abstract

Abstract Purpose: COVID has increased the rates of late cancer diagnoses. Clinicians need to be aware of which patients are at higher risk of receiving a late cancer diagnosis, in order to deliver appropriate and timely care planning and minimise avoidable late diagnoses. We aimed to determine which demographic and clinical factors are associated with receiving a ‘late’ cancer diagnosis (within the last 12 weeks of life). Method: Retrospective cohort study of 2,443 people who died from cancer (‘cancer decedents’) in 2013-2015. Demographic and cancer registry datasets linked using patient-identifying Community Health Index numbers. Analysis used binary logistic regression, with univariate and adjusted odds ratios (SPSS v25). Results : One third (n=831,34.0%) received a late diagnosis. Age and cancer type were significantly associated with late cancer diagnosis (p<0.001). Other demographic factors were not associated with receiving a late diagnosis. Cancer decedents with lung cancer[i]were more likely to have late diagnosis than those with bowel (95%CI 1.52 (1.12 to 2.04)), breast or ovarian (95%CI 3.33 (2.27 to 5.0) or prostate (95%CI (9.09 (4.0 to 20.0)) cancers. Cancer decedents aged >85 years had higher odds of late diagnosis (95%CI 3.45 (2.63 to 4.55)), compared to those aged <65 years. Conclusions: Cancer decedents who were older and those with lung cancer were significantly more likely to receive late cancer diagnoses than those who were younger or who had other cancer types. [i] Odds Ratios presented in abstract are the inverse of those presented in the main text, where lung cancer is the reference category. Presented as 1/(OR multivariate).

Publisher

Research Square Platform LLC

Reference38 articles.

1. Cancer Research UK. Cancer Statistics for the UK, 2020).

2. Ferlay J, et al. GLOBOCAN. 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer. Lyon: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr.

3. Information Services Division (ISD). Report. Cancer Mortality in Scotland. A National Statistics Publication for Scotland; 2015.

4. Saving lives, averting costs: An analysis of the financial implications of achieving earlier diagnosis of colorectal, lung and ovarian cancer;Cancer Research UK,2014

5. Routes to diagnosis for cancer – determining the patient journey using multiple routine data sets;Elliss-Brookes L;Br J Cancer,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3